Boosting leukemia-specific T cell responses in patients following stem cell transplantation.
Whole tumor cell-based vaccines administered within the first 2 to 3 months after allogeneic stem cell transplantation stand out as a promising approach to enhance graft-vs.-leukemia responses. Herein, the implications of this finding for the development of strategies to improve the outcome of patients subjected to allogeneic stem cell transplantation are discussed.
Department of Medical Oncology; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA.
Ute E
UE
Burkhardt
Department of Medical Oncology; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA ; Department of Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston, MA USA.
Catherine J
CJ
Wu
CLL; cancer vaccines; immune reconstitution; multiepitope vaccines; neoantigens; stem cell transplantation; whole tumor-cell vaccination